Synairgen (SNG)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

4.63p
   
  • Change Today:
      0.040p
  • 52 Week High: 9.80p
  • 52 Week Low: 3.40p
  • Currency: UK Pounds
  • Shares Issued: 202.66m
  • Volume: 27,287
  • Market Cap: £9.38m
  • RiskGrade: 510
  • Beta: 1.51

Latest ShareCast News

Synairgen names Joseph Colliver as CFO

By Iain Gilbert

Date: Wednesday 11 Oct 2023

(Sharecast News) - Drug discovery firm Synairgen revealed on Wednesday that it had tapped Joseph Colliver to take over as chief financial officer.

Synairgen posts positive results for phase 2 trial with SNG001 against Covid-19

By Alexander Bueso

Date: Tuesday 04 Oct 2022

(Sharecast News) - Synairgen announced positive results for its inhaled antiviral protein treatment interferon beta against Covid-19.

Synairgen unveils positive clinical trial data

By Abigail Townsend

Date: Wednesday 07 Sep 2022

(Sharecast News) - Respiratory drug discovery firm Synairgen has announced positive findings from a clinical trial into its experimental antiviral treatment.

Synairgen to collaborate with University of Sout... 05-Sep-2022 ShareCast
Synairgen posts positive clinical trial data for... 16-May-2022 ShareCast
Synairgen falls as patient recruitment halted on... 17-Mar-2022 ShareCast
Synairgen asked to pause activities on Covid-19 ... 03-Mar-2022 ShareCast
Synairgen shares plunge as Covid-19 treatment tr... 21-Feb-2022 ShareCast
Synairgen secures patients for phase III study o... 11-Nov-2021 ShareCast
Synairgen drug proves effective against Covid va... 24-May-2021 ShareCast
Synairgen confirms start of dosing in Covid-19 t... 15-Feb-2021 ShareCast
Synairgen enters clinical trial deal with US gov... 25-Jan-2021 ShareCast
Synairgen completes recruitment for at-home Covi... 20-Jan-2021 ShareCast
Synairgen starts final-stage trial for Covid-19 ... 13-Jan-2021 ShareCast
Synairgen makes solid progress with Covid-19 tre... 18-Dec-2020 ShareCast
Synairgen surges on positive results for Covid-1... 13-Nov-2020 ShareCast
Synairgen files for another patent on 'SNG001' 09-Sep-2020 ShareCast
Synairgen upbeat on latest data from SNG001 trials 08-Sep-2020 ShareCast
Europe open: Stocks reverse early losses, health... 20-Jul-2020 ShareCast
Synairgen treatment reduces risk of 'severe' Cov... 20-Jul-2020 ShareCast
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Synairgen Market Data

Currency UK Pounds
Share Price 4.63p
Change Today 0.040p
% Change 0.87 %
52 Week High 9.80p
52 Week Low 3.40p
Volume 27,287
Shares Issued 202.66m
Market Cap £9.38m
Beta 1.51
RiskGrade 510

Synairgen Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
52.77% above the market average52.77% above the market average52.77% above the market average52.77% above the market average52.77% above the market average
80.00% above the sector average80.00% above the sector average80.00% above the sector average80.00% above the sector average80.00% above the sector average
Price Trend
79.28% below the market average79.28% below the market average79.28% below the market average79.28% below the market average79.28% below the market average
63.27% below the sector average63.27% below the sector average63.27% below the sector average63.27% below the sector average63.27% below the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 0
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 1
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Synairgen Dividends

No dividends found

Trades for 21-Nov-2024

Time Volume / Share Price
15:53 46 @ 4.92p
15:35 3,129 @ 4.40p
15:09 4,000 @ 4.40p
13:55 2,503 @ 4.72p
13:03 8,609 @ 4.40p

Synairgen Key Personnel

CEO Richard J Marsden

Top of Page